Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)

Table 1 Patient and tumor characteristics

Patient and treatment characteristics			p-value
Age	Median	65	0,36
Age	Range	44–83	0,36
KPS	Median	70	0,1
KPS	Range	50–90	0,1
Sex	Male	45	0,13
Sex	Female	21	0,13
Weight loss > 5 %	None	49	0,7
Weight loss > 5 %	Yes	17	0,7
Stage	T	T1: 14	<0,001
		T2: 32
		T3: 11
		T4:9
	N	N0: 3	0,07
		N1: 7
		N2: 43
		N3: 13
	UICC	II: 4	x
		IIIA: 44
		IIIB: 18
Tumor location	right lung	36	0,8
	left lung	30	0,8
	upper lobe	48	0,44
	middle lobe	2
	lower lobe	16
	peripheral	38	0,33
	central	28	0,33
Histology	SCC	39	0,26
	AC	21
	NOS	6
Group	I (<2,5 cm)	12	x
	II (2,5–4,5 cm)	32
	III (4,5–6 cm)	13
	IV (>6 cm)	9
PTV tumor (ml)	Median	93	<0,001
PTV tumor (ml)	Range	16–528	<0,001
Tumor dose (Gy)	Median	79,2	<0,001
Tumor dose (Gy)	Range	73,8–90	<0,001
Lymph node dose (Gy)	Median	61	0,38
Lymph node dose (Gy)	Range	0–90	0,38
ENI^a (Gy)	Median	45	0,43
ENI^a (Gy)	Range	0–63	0,43

The distribution of patient and tumor characteristics over the four dose groups was tested with the Kruskal-Wallis-Test (x = not tested, ^a = elective nodal irradiation). Significant differences were found – as expected – in group-related parameters (T-stage, N-stage, tumor dose, PTV tumor)

ISSN: 1748-717X